146 related articles for article (PubMed ID: 28219443)
1. A new framework for evaluating the health impacts of treatment for Gaucher disease type 1.
Ganz ML; Stern S; Ward A; Nalysnyk L; Selzer M; Hamed A; Weinreb N
Orphanet J Rare Dis; 2017 Feb; 12(1):38. PubMed ID: 28219443
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
[TBL] [Abstract][Full Text] [Related]
3. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients.
Serai SD; Naidu AP; Andrew Burrow T; Prada CE; Xanthakos S; Towbin AJ
Mol Genet Metab; 2018 Mar; 123(3):357-363. PubMed ID: 29361370
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease: hematologic and oncologic implications.
Hughes D
Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
[No Abstract] [Full Text] [Related]
5. Retrospective Analysis of Whole-Body Magnetic Resonance Imaging of Bone Manifestations in Long-Term Treated Patients with Gaucher Disease Type 1.
Lollert A; Laudemann K; Mengel E; Hoffmann C; Moos L; Reinke J; Brixius-Huth M; Hennermann JB; Düber C; Staatz G
Klin Padiatr; 2019 Mar; 231(2):52-59. PubMed ID: 30481833
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
7. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
8. A validated disease severity scoring system for adults with type 1 Gaucher disease.
Weinreb NJ; Cappellini MD; Cox TM; Giannini EH; Grabowski GA; Hwu WL; Mankin H; Martins AM; Sawyer C; vom Dahl S; Yeh MS; Zimran A
Genet Med; 2010 Jan; 12(1):44-51. PubMed ID: 20027115
[TBL] [Abstract][Full Text] [Related]
9. Goal-oriented therapy with miglustat in Gaucher disease.
Pastores GM; Giraldo P; Chérin P; Mehta A
Curr Med Res Opin; 2009 Jan; 25(1):23-37. PubMed ID: 19210136
[TBL] [Abstract][Full Text] [Related]
10. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
11. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
12. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
13. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
14. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
Stein P; Malhotra A; Haims A; Pastores GM; Mistry PK
J Inherit Metab Dis; 2010 Dec; 33(6):769-74. PubMed ID: 20683668
[TBL] [Abstract][Full Text] [Related]
15. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
[TBL] [Abstract][Full Text] [Related]
16. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
17. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
18. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
20. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
